Spiration Valve System
Gyrus Acmi, Inc. · Decision date Aug 20, 2026
What did the FDA approve?
FDA records P180007/S016 as a supplement to PMA P180007, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Aug 20, 2026.
FDA approval order statement
Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P180007.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Anesthesiology
- Decision date
- Aug 20, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P180007/S016
- Regulatory pathway
- PMA supplement
- Applicant
- Gyrus Acmi, Inc.
- Product code
- NJK
- Decision code
- APPR
- Decision date
- Aug 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Valve, pulmonary.
- Applicant
- Gyrus Acmi, Inc.
- Product code
- NJK
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P180007/S015 · Related supplement
Spiration Valve System (SVS)
P180007/S016 received
Application receipt date recorded by FDA.
P180007/S016 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P180007. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P180007
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Spiration Valve System (SVS)P180007/S015 | Gyrus Acmi, Inc. | PMA supplement | May 7, 2026 | FDA |
Explore the linked device profile
Other records with product code NJK
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Zephyr Endobronchial Valve SystemP180002/S032 | Pulmonx Corporation | PMA supplement | Sep 11, 2026 | FDA |
Zephyr Endobronchial Valve (EBV) SystemP180002/S031 | Pulmonx Corporation | PMA supplement | Jun 17, 2026 | FDA |
Zephyr Endobronchial Valve (EBV) SystemP180002/S030 | Pulmonx Corporation | PMA supplement | Mar 17, 2026 | FDA |
| Pulmonx Corporation | PMA approval | Jun 29, 2018 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Gyrus Acmi, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6675 185th Ave. NE, Redmond, WA, 98052
Sources and methodology
- Original FDA record: P180007/S016
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records